This page cites peer-reviewed literature, FDA records, and published case reports. No affiliate relationships with peptide vendors. Confidence ratings follow GRADE conventions.
Key Takeaways
- MT2 (Melanotan II) is not FDA-approved for any human use and cannot legally be sold as a drug or compounded medication in the United States as of 2026.
- Small University of Arizona human trials in the 1990s confirmed pigmentation effects, but sample sizes were under 20 subjects and no long-term safety data exists.
- MT2 binds MC1R through MC5R non-selectively, which is both why it works for tanning and why it causes unwanted erections, nausea, and potential nevi stimulation simultaneously.
- Multiple case reports in peer-reviewed dermatology journals link MT2 use to new or changing melanocytic nevi and, in some reports, melanoma; causality is unproven but the signal is real.
- The FDA-approved alternative for photoprotection via melanocortin stimulation is afamelanotide (Scenesse), restricted to erythropoietic protoporphyria patients and administered by a physician.
Direct Answer: Where Can I Find MT2 Peptide Near Me?
You can find vendors selling MT2 locally or online as a "research chemical," but you should not inject it obtained this way. Melanotan II has no FDA approval, no approved compounding pathway, and real safety signals including nevi changes and cardiovascular effects. The search question matters less than the decision framework behind it.
Table of Contents
- What is MT2 and how does it work?
- Evidence ledger: what the data actually supports
- The mechanism with real numbers
- What is the legal status of MT2 near me?
- What most pages get wrong about MT2
- What are the real safety signals?
- Honest head-to-head: MT2 vs. real alternatives
- How to read a COA and spot a bad product
- Storage and formulation: the chemistry behind the rules
- Frequently Asked Questions
- Sources
What Is MT2 and How Does It Work?
Melanotan II is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), first synthesized at the University of Arizona in the late 1980s. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The cyclic structure and D-phenylalanine substitution confer resistance to enzymatic degradation compared to native alpha-MSH, extending its biological half-life from minutes to roughly 30 to 60 minutes in vivo.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Unlike its linear cousin afamelanotide, MT2 binds all five melanocortin receptor subtypes (MC1R through MC5R) with high affinity and without meaningful selectivity. That receptor promiscuity drives everything: the tanning effect, the sexual side effects, and the safety concerns all emerge from the same non-selective binding profile.
Evidence Ledger: What the Data Actually Supports
| Claim | Best evidence type | Effect direction | Confidence (GRADE) |
|---|---|---|---|
| MT2 increases skin pigmentation in fair-skinned humans | Small human trials (Hadley et al., Dorr et al., University of Arizona, 1990s); n under 20 per study | Positive, measurable | Low |
| MT2 induces penile erection via MC4R | Small RCT in men with psychogenic ED (Wessells et al., 1998); n=10 | Positive; erections occurred more frequently with MT2 than placebo | Low |
| MT2 suppresses appetite | Animal models (rodent); no adequately powered human RCT | Positive in animals | Very low |
| MT2 stimulates existing nevi or promotes melanoma | Case reports (British Journal of Dermatology, other dermatology journals); no RCT | Signal present, causality unproven | Very low (but clinically concerning) |
| MT2 causes nausea and facial flushing | Consistent across all human trials and case series | Adverse, dose-dependent | Moderate |
| MT2 affects blood pressure | Pharmacodynamic data from small trials; mechanism via MC3R/MC4R vascular effects | Mixed; transient changes reported | Low |
| Gray-market MT2 matches claimed purity | Independent HPLC testing studies of research chemical peptides (various labs, 2010s) | Frequently fails purity standards | Moderate (for the failure rate) |
The Mechanism with Real Numbers
MT2 is an agonist at all five melanocortin receptors. The IC50 values for MT2 at human MC1R through MC4R are in the low nanomolar range (roughly 0.2 to 4 nM depending on the receptor and assay), making it potent but indiscriminate.
- MC1R (tanning): Expressed on melanocytes. Activation upregulates tyrosinase via cAMP-PKA-MITF signaling, increasing eumelanin synthesis. This produces darker, UV-independent pigmentation. It does NOT protect against UVB-induced DNA damage as effectively as a natural tan built from UV exposure, because UV also triggers local DNA repair responses that MT2-driven tanning bypasses.
- MC3R and MC4R (appetite, arousal): Central nervous system receptors in the hypothalamus and limbic system. MC4R is the target through which MT2 drives penile erection (via oxytocin release) and appetite suppression. The Wessells et al. crossover trial (1998) in men with psychogenic ED demonstrated that MT2 induced erections significantly more often than placebo in this small study (n=10), though the trial was not powered for broader efficacy conclusions.
- MC5R (exocrine glands): Affects sebaceous and lacrimal glands. Clinical relevance in humans at typical MT2 doses is not well characterized.
What the mechanism does NOT prove: Nanomolar receptor affinity in a binding assay does not prove efficacy, safety, or optimal dose in a free-living human. It also does not address the behavior of the non-peptide impurities that gray-market vials frequently contain.
What Is the Legal Status of MT2 Near Me?
In the United States, MT2 (Melanotan II) has no FDA approval for any indication. The FDA issued warning letters to US-based MT2 sellers, most prominently in 2015 and later years, citing illegal marketing as a drug. The compound cannot legally be compounded by a 503A or 503B pharmacy for human use because it is not on any approved compounding list.
In the UK, MT2 was classified as a Class C controlled substance in 2015 under the Misuse of Drugs Act, making supply illegal. Australia and several EU nations have similar bans. Always verify local law before searching "MT2 peptide near me."
What Most Pages Get Wrong About MT2
This is the section competitors skip. Here are the four things most MT2 guides omit or misrepresent:
1. The "loading dose" narrative has no clinical basis. The common protocol of 0.25 mg to 0.5 mg daily escalating to a "saturation" dose is derived from bodybuilder forum consensus, not from any clinical dosing study. Hadley's trials used measured subcutaneous doses in a controlled setting with baseline skin typing. Forum protocols are extrapolations that ignore body weight, phototype, and co-medications.
2. MT2 does not provide UV-equivalent photoprotection. Melanin from MT2 increases Fitzpatrick skin phototype appearance, but because it bypasses the UV-triggered p53 response and local DNA repair upregulation, the photoprotective effect is not the same as a natural tan built from actual UV exposure. Relying on MT2-induced pigmentation to reduce sunburn risk is not validated.
3. Solvent choice for reconstitution matters and most guides ignore it. MT2 is typically reconstituted with bacteriostatic water (0.9% benzyl alcohol preserved sterile water). Using plain sterile water without a preservative allows bacterial growth within days at refrigerator temperature. Using acetic acid (sometimes recommended for other peptides) can accelerate degradation of the His residue in the MT2 sequence.
4. Nevi stimulation is an underweighted risk. Most tanning-focused guides mention nausea as the main side effect and downplay the nevus signal. The British Journal of Dermatology has published case reports of rapid pigmentary changes in nevi attributed to MT2 use, and dermatologists who see MT2 users routinely recommend full skin mapping before and after use. This is not fearmongering; it is standard oncologic caution given MC1R's known role in melanoma biology.
What Are the Real Safety Signals?
Safety data for MT2 comes from small trials, case reports, and spontaneous adverse event reports, not from large, powered safety studies. Key signals:
- Nausea and vomiting: Dose-dependent, reported in essentially every human trial. Reducing the dose and injecting at night reduces but does not eliminate it.
- Spontaneous erections: Occur in men regardless of whether this is the intended effect. Reported as distressing in some clinical contexts.
- Melanocytic nevus changes: Multiple case reports. One widely cited case in the British Journal of Dermatology described rapid darkening and size increase of multiple nevi during a short MT2 course. Malignant transformation cases have been reported but causality is debated.
- Cardiovascular effects: Transient blood pressure changes have been recorded in pharmacodynamic studies. The mechanism involves MC3R and MC4R in vascular and renal tissue.
- Injection site and sterility risks: Gray-market products in non-GMP vials carry real bacterial and endotoxin contamination risk.
Honest Head-to-Head: MT2 vs. Real Alternatives
| Attribute | MT2 (Melanotan II) | Afamelanotide (Scenesse) | DHA Self-Tanners | Bremelanotide (Vyleesi, for sexual use) |
|---|---|---|---|---|
| FDA approval | None | Yes (EPP only, 2019) | Color additive (recognized) | Yes (HSDD in women, 2019) |
| Tanning efficacy evidence | Low confidence (small trials) | Moderate (phase III in EPP) | High (cosmetic standard) | N/A |
| Receptor selectivity | Non-selective MC1R to MC5R | More MC1R-selective | No receptor activity | MC3R, MC4R predominant |
| Route | Subcutaneous injection | Subcutaneous implant (physician) | Topical | Subcutaneous auto-injector |
| Nevi/melanoma risk signal | Yes (case reports) | Monitored in trials; lower signal | None | Uncertain; not studied long-term |
| Legal to obtain locally (US) | No | Prescription only, restricted REMS | Yes, OTC | Prescription only |
| Where MT2 loses | Legal status, safety data, selectivity, purity assurance | Narrower indication, no cosmetic use | No systemic effect at all | Not approved for tanning or ED |
How to Read a COA and Spot a Bad MT2 Product
If you are evaluating any peptide from a research chemical vendor, here is what a legitimate certificate of analysis (COA) must contain. The absence of any of these is a red flag:
- Analytical method: HPLC (high-performance liquid chromatography) for purity percentage. Mass spectrometry (MS) for molecular weight confirmation, confirming the correct peptide sequence and not a truncation or scrambled analog.
- Purity threshold: Research-grade peptide should show at least 98% purity by HPLC. Anything below 95% is generally considered substandard for any use.
- Third-party lab name: The COA should name the independent testing laboratory. A COA generated internally by the same company selling the product has very limited value.
- Lot number match: The lot number printed on the COA must match the vial. A COA from a different batch is meaningless for your vial.
- Endotoxin testing: For anything intended for injection, a LAL (Limulus Amebocyte Lysate) endotoxin test result should be present. Most gray-market research chemical COAs do not include this. Its absence means you cannot rule out pyrogen contamination.
What degraded MT2 looks like: Fresh lyophilized MT2 is a white to off-white powder that collapses slightly into a cake form. Yellow or brown discoloration indicates oxidative degradation of the Trp (tryptophan) or His (histidine) residues in the MT2 sequence. Liquid or wet powder suggests the lyophilization failed. Reconstituted MT2 should be clear and colorless. Cloudiness or particulate matter means contamination. Do not inject any of these.
Storage and Formulation: The Chemistry Behind the Rules
Why cold storage matters: Peptide bonds are stable at physiological pH under cold conditions, but thermal energy accelerates hydrolysis of the Asp residue in MT2's cyclic core. At room temperature, reconstituted peptide degradation accelerates significantly compared to 2 to 8 degrees Celsius storage. This is not a marketing rule; it reflects standard peptide solution stability chemistry.
Why light exposure degrades MT2: The Trp (tryptophan) residue in the MT2 sequence is susceptible to photooxidation. UV and visible light generate reactive oxygen species that oxidize the indole ring of Trp, converting it to kynurenine and other products that are biologically inactive. This is why amber vials and opaque storage matter, not just marketing aesthetics.
Why freeze-thaw cycles hurt: Ice crystal formation during freezing of a reconstituted peptide solution physically disrupts peptide aggregation states and can accelerate denaturation on thawing. Lyophilized (dry) powder can tolerate freeze storage well; reconstituted solution should not be repeatedly frozen and thawed.
Why bacteriostatic water, not sterile water: Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth in a multi-use vial. Plain sterile water has no preservative. A reconstituted peptide vial opened and re-used over days without bacteriostatic water becomes a bacterial culture medium within a week at refrigerator temperature.
Frequently Asked Questions
Can I legally buy MT2 peptide near me in the United States?
Melanotan II is not FDA-approved for any human use. It cannot legally be sold as a drug, dietary supplement, or compounded medication in the US. It exists in a gray market as a "research chemical," and purchasing it for human injection carries real legal and health risk.
What does MT2 actually do in the body?
MT2 is a synthetic analog of alpha-MSH that binds non-selectively to melanocortin receptors MC1R through MC5R. MC1R activation increases melanin production (tanning). MC3R and MC4R activation suppresses appetite and increases sexual arousal. MC5R effects include sebum and exocrine gland modulation.
Is there human trial evidence that MT2 works for tanning?
Yes, small human trials in the 1990s by Hadley and colleagues at the University of Arizona demonstrated measurable increases in skin pigmentation with subcutaneous MT2. However, sample sizes were very small (under 20 subjects), trials were short, and none were powered for safety outcomes. Evidence quality is Low by GRADE standards.
What are the most dangerous side effects of MT2?
Nausea and facial flushing are common. More serious concerns include spontaneous penile erections, blood pressure changes, and stimulation of existing melanocytic nevi. Multiple case reports link MT2 use to melanoma development, though causality is not proven. Unregulated injectable products also carry infection risk.
How is MT2 different from afamelanotide (Scenesse)?
Afamelanotide (Scenesse) is a linear alpha-MSH analog approved by the FDA in 2019 for erythropoietic protoporphyria. It is more MC1R-selective than MT2, delivered as a subcutaneous implant under physician supervision, and has real phase III safety data. MT2 is a cyclic, non-selective analog with no regulatory approval.
What does a degraded or counterfeit MT2 vial look like?
Legitimate lyophilized MT2 powder is white to off-white and collapses into a fine cake. Yellow, brown, or liquid-appearing powder indicates oxidative degradation or improper lyophilization. Cloudy reconstituted solution suggests contamination or particulate matter. These vials should not be injected.
Why do so many local clinics and wellness spas offer MT2 if it is not approved?
Gray-market research chemical supply chains allow clinics to source MT2 without prescription requirements. Some operate under the premise that "research only" labeling reduces liability. FDA enforcement against individual clinics has been inconsistent, which creates a false sense of legality for consumers.
Does MT2 help with erectile dysfunction?
MT2 triggers erections via MC4R activation in the hypothalamus and spinal cord. Small trials showed it induced erections in men with psychogenic ED. However, bremelanotide (Vyleesi), a closely related peptide, is FDA-approved for hypoactive sexual desire disorder in women; it is not approved for ED, and MT2 itself is not approved at all.
How should MT2 be stored to prevent degradation?
Lyophilized MT2 should be stored at 2 to 8 degrees Celsius, protected from light. Once reconstituted with bacteriostatic water, it should be refrigerated and used within 28 to 30 days per standard peptide handling practice. Freeze-thaw cycles degrade the peptide structure and reduce potency.
What is the real alternative to MT2 for cosmetic tanning?
Self-tanning products using dihydroxyacetone (DHA) are the only legally available, externally applied tanning agents with a well-established safety profile and FDA recognition under the color additive framework. They carry no systemic receptor activity and no injection risk.
Can MT2 cause changes to moles or nevi?
Yes. Because MT2 stimulates MC1R non-selectively across all melanocytes, it can activate pigment production in existing nevi. Case reports published in the British Journal of Dermatology and elsewhere document new or changing nevi and melanoma in MT2 users. Dermatologists recommend a baseline and follow-up skin check if someone has used MT2.
How can I read a COA for a peptide to judge purity?
A credible COA should specify the analytical method (HPLC for purity, mass spectrometry for molecular identity), show purity of at least 98 percent for research-grade peptide, identify the testing laboratory by name, and match the lot number on the vial. A COA from the vendor's own internal lab without third-party verification has very limited value.
Sources
- Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS, Hadley ME. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology. 2004;140(7):827-835.
- Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. 1998;160(2):389-393.
- Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed Melanotan. BMJ. 2009;338:b1786.
- Coelho SG, Hearing VJ. UVA tanning is involved in the increased incidence of skin cancers in fair-skinned young women. Pigment Cell and Melanoma Research. 2010;23(1):57-63.
- FDA Warning Letters to Melanotan II sellers. US Food and Drug Administration. Multiple years including 2015. Available at: fda.gov
- Clinuvel Pharmaceuticals. Scenesse (afamelanotide) FDA approval summary. 2019. NDA 210797.
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.
- Cone RD. Anatomy and regulation of the central melanocortin system. Nature Neuroscience. 2005;8(5):571-578.
- UK Home Office. Misuse of Drugs Act 1971, Amendment Order 2015 (Melanotan II classification). London: HMSO.
- Manning P. Dihydroxyacetone as a self-tanning agent: safety and regulatory status. International Journal of Cosmetic Science. Review literature, various years.